ADAM17 and cancer: In cancer cells, TRAF6 also engages and activates proteolytic enzymes such as ADAM17/TACE and presenilin-1 (PSEN1 or PS1), which leads to the generation and release of the TGFβRI intracellular domain (TGFβRI-ICD) [47,48].